TITLE:
Oral SAHA (Suberoylanilide Hydroxamic Acid) in Advanced Cutaneous T-cell Lymphoma (0683-001)

CONDITION:
Cutaneous T-cell Lymphoma

INTERVENTION:
MK0683, vorinostat, Suberoylanilide Hydroxamic Acid (SAHA) / Duration of Treatment 6 Months

SUMMARY:

      A study for patients diagnosed with advanced cutaneous T-cell lymphoma (stage 1B or higher)
      who have progressive, persistent, or recurrent disease on or following 2 other therapies,
      one of which must have contained Targretin (bexarotene)or for patients who are not
      candidates or could not tolerate Targretin therapy.
    

DETAILED DESCRIPTION:
NONE

ELIGIBILITY:
Gender: All
Age: 18 Years to N/A
Criteria:

        Inclusion Criteria:

          -  Patients with Cutaneous T-cell Lymphoma (Stage 1B or higher)

          -  Age: over 18 years of age

          -  Have the ability to swallow capsules.

          -  You must be at least 3 weeks from any prior chemotherapy or anticancer therapy
             treatment and have recovered from any side effects of that treatment.

          -  Patients also require adequate heart, liver, and kidney function.

        Exclusion Criteria:

          -  Pregnant and nursing women and those with known allergy to the study drug are
             excluded from this study.

          -  Patients are excluded if they are currently receiving chemotherapy, radiation
             therapy, or other investigational anti-cancer therapy.

          -  Patients diagnosed with HIV, active hepatitis or who require intravenous antibiotics
             or antifungal agents are not permitted.
      
